AbstractBackground and objectivesCuring Mycoplasma genitalium is challenging in the context of rising antimicrobial resistance and limited therapeutic options. There is an urgent need for globally relevant and effective treatment options using readily available and affordable agents. From September 2021 to August 2024 at Melbourne Sexual Health Centre, we prospectively evaluated microbial cure and tolerability of oral minocycline 100?mg combined with metronidazole 400?mg (twice daily for 14 days) for individuals with macrolide-resistant M. genitalium in whom fluroquinolones had failed or were not advised.MethodsMicrobial cure was defined as a negative test of cure (TOC) using transcription-mediated amplification 14–90 days after completing the regimen. The proportion cured and 95% confidence intervals (CIs) were calculated. Data on side effects and adherence were collected at TOC visits.ResultsMicrobial cure in patients receiving the combination regimen was 80.8% (95% CI: 71.9–87.8%). Cure in those who had received preceding doxycycline was 90.3% (n?=?28/31, 95% CI: 74.2–98.0%) compared to 76.7% (n?=?56/73, 95% CI: 65.4–85.8%) in those who had not, P?=?0.172. Central nervous system and gastrointestinal side effects were commonly reported.ConclusionsMinocycline with metronidazole cured 80% of macrolide-resistant infections in this cohort. Cure may be enhanced by the use of doxycycline before the combination regimen but larger studies are needed. Given limited options for treating resistant M. genitalium infections, the combined minocycline and metronidazole regimen may represent a promising option where no alternative drugs are available, or quinolones are contraindicated. Clinicians should be aware of and discuss side effects with patients.

As of April 24, 2025, 32 cases of yellow fever, including 11 deaths, have been confirmed in Peru. All infections were in individuals with a history of exposure to wild or wooded areas due to hunting or agricultural work. 23 (72%) infections were in individuals with no history of vaccination against yellow fever. The Peruvian Ministry of Health announced they will intensify response actions, epidemiological surveillance, and vaccination against yellow fever in response to the epidemic.

An 81-year-old man with IgG hypogammaglobulinemia on intravenous immunoglobulin infusions, chronic sinusitis treated with nasal rinses, and a complex history of progressive destruction of the nasal architecture, presented to the dermatology department for ulceration of the upper lip. Examination revealed a 40 mm by 15 mm crusted and eroded plaque of the mucosal and cutaneous upper lip (figure A). Biopsy showed an impetiginised ulcer with dense, mixed inflammation in the dermis and amoebic trophozoites highlighted with periodic acid-Schiff stain, consistent with a free-living amoeba infection (figure D).

Excision BioTherapeutics, Inc. (Excision), a biotechnology company developing CRISPR─based therapies to cure viral infectious diseases, announced publication of a preprint demonstrating proof─of─concept

Hepatocellular carcinoma (HCC) represents a significant global health challenge, with chronic hepatitis B (CHB) being the primary cause in East Asia. Despite antiviral treatments reducing HCC risk, early detection through surveillance remains essential. Shin, Hur, Song, Park, Kim, and coworkers created an artificial intelligence (AI) HCC prediction model called PLAN-B-DF that incorporates six imaging biomarkers (from abdominal CT scans) and eight clinical variables as its primary components. PLAN-B-DF demonstrated an excellent predictive performance in the internal validation set and significantly outperformed previous models in the external validation cohort.

Inhaled aerosols, the cornerstone in the everyday therapeutic management of patients with asthma, target drug directly to their pathophysiological sit...

Inconsistent results have been obtained with various antibiotics for community-acquired pneumonia (CAP) in hospitalized adults. We performed a Bayesian network meta-analysis to compare and rank the effectiveness of antibiotics for adult patients with CAP.

Inconsistent results have been obtained with various antibiotics for community-acquired pneumonia (CAP) in hospitalized adults. We performed a Bayesian network meta-analysis to compare and rank the effectiveness of antibiotics for adult patients with CAP.

We read with great interest the Review by Oliver A Cornely and colleagues1 presenting the recent global guideline for the diagnosis and management of candidiasis. The guideline was developed by the European Confederation of Medical Mycology in cooperation with the International Society of Human and Animal Mycology and American Society for Microbiology. This initiative represents an important effort to synthesise available evidence and offer practical guidance for clinicians managing rare and complex invasive fungal infections.

We thank Aurélien Dinh and colleagues for their thoughtful comments on our recently published global guideline on the diagnosis and management of candidiasis.1 The authors rightly highlight the ongoing uncertainty surrounding the optimal duration of treatment of candidiasis with bone and joint involvement.